ArticleClinical epigenetics2024

MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.

Hanghang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.